Notably, the downregulation of ABR, PREX1, DOCK2, and DOCK4 are associated with poor overall survival of NSCLC patients, suggesting that these four novel Rho GEFs can serve as promising biomarkers for predicting the OS of patients. This evidence concerns the gene DOCK4 and non-small cell lung carcinoma.